Short answer
ACTUATE THERAPEUTICS, INC. (ACTU) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$5M
- +9.4% YoY · +9.1% QoQ
- EPS (diluted)
- −$0.25
- −104.9% YoY · +19.4% QoQ
Source: XBRL data from the ACTUATE THERAPEUTICS, INC. (ACTU) Q3 2025 10-Q on SEC EDGAR. USD.
ACTUATE THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or materially updated risk factors disclosed compared to most recent 10-K
- Regulatory risk: ongoing compliance with FDA and global regulatory bodies remains critical for product approvals
- Operational risk: dependence on successful clinical trial outcomes to meet near-term milestones and maintain market competitiveness
- Financial risk: liquidity constrained, requiring additional funding to support operations and clinical development programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACTUATE THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.